Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Industry
Pharmaceutical Preparations
Location
6 Liberty Square, #2382, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 160 % +16.4%
Debt-to-equity 131 % -36.9%
Return On Equity -649 % +21%
Return On Assets -281 % -5.15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.3M shares -14.1%
Common Stock, Shares, Outstanding 17.3M shares +61.5%
Entity Public Float 4.4M USD -60%
Common Stock, Value, Issued 1.73K USD +61.6%
Weighted Average Number of Shares Outstanding, Basic 14.7M shares +13322%
Weighted Average Number of Shares Outstanding, Diluted 14.7M shares +13322%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.43M USD -18.6%
General and Administrative Expense 5.23M USD -43.3%
Operating Income (Loss) -14.7M USD +29.5%
Nonoperating Income (Expense) -261K USD -121%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -14.9M USD +23.8%
Earnings Per Share, Basic 345 USD/shares +99.7%
Earnings Per Share, Diluted 345 USD/shares +99.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.88M USD -74.8%
Assets, Current 3.61M USD -61.5%
Property, Plant and Equipment, Net 61.4K USD -59.7%
Operating Lease, Right-of-Use Asset 150K USD -74.5%
Assets 3.94M USD -61.5%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 2.28M USD -59.2%
Operating Lease, Liability, Noncurrent 38.3K USD
Liabilities 2.28M USD -60.5%
Retained Earnings (Accumulated Deficit) -57.3M USD -35.3%
Stockholders' Equity Attributable to Parent 1.65M USD -62.8%
Liabilities and Equity 3.94M USD -61.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD +12.8%
Net Cash Provided by (Used in) Financing Activities 6.09M USD +416%
Net Cash Provided by (Used in) Investing Activities -3.84K USD +70.3%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 17.3M shares +61.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.15M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.88M USD -74.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.65K USD -31.9%
Deferred Tax Assets, Valuation Allowance 12.7M USD +76.9%
Deferred Tax Assets, Gross 12.7M USD +76.9%
Operating Lease, Liability 152K USD -74.4%
Depreciation 32.2K USD +8.52%
Payments to Acquire Property, Plant, and Equipment 3.84K USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 154K USD -74.8%
Property, Plant and Equipment, Gross 405K USD +5.54%
Operating Lease, Liability, Current 152K USD -62.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD -91.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03K USD -93.2%
Deferred Tax Assets, Operating Loss Carryforwards 5.88M USD +71.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 353K USD
Operating Lease, Payments 348K USD -40.8%
Additional Paid in Capital 58.9M USD +26%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 112K USD -7.52%
Share-based Payment Arrangement, Expense 198K USD +25.1%
Interest Expense 42.3K USD -37.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%